Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Addendum to Project A23-94

Report documents

1. Addendum

   Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Addendum to Project A23-94

   published on

   21.03.2024

   Document type

   PDF document, 317 kB, EN, not accessible

   DOI-Link

   https://doi.org/10.60584/A24-23_en

   Download file : Addendum (PDF document, 317 kB, EN, not accessible)

Additional information

Project details

Project no.

A24-23

Commission

Commission awarded on 06.03.2024 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Drug Assessment

Topic

Cancer

Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://dx.doi.org/10.60584/A24-23_en

Connected Projects

1. Dossier assessment

   Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Benefit assessment according to §35a Social Code Book V

   Project no.

   A23-94

   Last updated

   21.03.2024

   Status: Commission completed

2. Dossier assessment

   Nivolumab (oesophageal or gastro-oesophageal junction cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V

   Project no.

   A25-88

   Last updated

   18.12.2025

   Status: Commission completed

3. Dossier assessment

   Nivolumab (urothelial carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)

   Project no.

   A25-154

   Last updated

   05.06.2026

   Status: Commission completed